Acrux Limited (AU:ACR) has released an update.
Acrux Limited is set to boost its revenue stream with the approval and upcoming launch of Dapsone 7.5% Gel, alongside another product, by early 2025. These launches are part of Acrux’s strategy to expand its portfolio of topically applied pharmaceuticals, which already includes three revenue-generating products in the U.S. market. The company has repaid its Radium short-term facility in full, thanks to a tax rebate, reflecting strong financial management.
For further insights into AU:ACR stock, check out TipRanks’ Stock Analysis page.
